Advanced search
Publication Cover
Polymer Reviews Volume 63, 2023 - Issue 2
Submit an article Journal homepage
859
Views
2
CrossRef citations to date
0
Altmetric
Reviews

Material Design for Next-Generation mRNA Vaccines Using Lipid Nanoparticles

Akon Higuchia School of Biomedical Engineering, The Eye Hospital of Wenzhou Medical University, Wenzhou Medical University, Wenzhou, Zhejiang, China; ;b Department of Chemical and Materials Engineering, National Central University, Jhongli, Taiwan; ;c R&D Center for Membrane Technology, Chung Yuan Christian University, Chungli, Taiwan; ;d Department of Reproduction, National Center for Child Health and Development, Okura, Tokyo, Japan; Correspondence[email protected]
View further author information
,
Tzu-Cheng Sunga School of Biomedical Engineering, The Eye Hospital of Wenzhou Medical University, Wenzhou Medical University, Wenzhou, Zhejiang, China; View further author information
,
Ting Wanga School of Biomedical Engineering, The Eye Hospital of Wenzhou Medical University, Wenzhou Medical University, Wenzhou, Zhejiang, China; View further author information
,
Qing-Dong Linge Cathay Medical Research Institute, Cathay General Hospital, Taipei, Taiwan; View further author information
,
S. Suresh Kumarf Department of Biotechnology, Bharath Institute of Higher Education and Research, Chennai, India; View further author information
,
Shih-Tien Hsug Department of Internal Medicine, Taiwan Landseed Hospital, Pingjen City, TaiwanTaoyuanView further author information
&
Akihiro Umezawad Department of Reproduction, National Center for Child Health and Development, Okura, Tokyo, Japan; View further author information
 show all
Pages 394-436 | Received 04 Nov 2021, Accepted 01 Jul 2022, Published online: 03 Aug 2022

References

  • Krammer, F. SARS-CoV-2 Vaccines in Development. Nature 2020, 586, 516–527. DOI: 10.1038/s41586-020-2798-3.
  • Le, T. T.; Cramer, J. P.; Chen, R.; Mayhew, S. Evolution of the COVID-19 Vaccine Development Landscape. Nat. Rev. Drug Discov. 2020, 19, 667–668. DOI: 10.1038/d41573-020-00151-8.
  • Deming, M. E.; Michael, N. L.; Robb, M.; Cohen, M. S.; Neuzil, K. M. Accelerating Development of SARS-CoV-2 Vaccines - The Role for Controlled Human Infection Models. N Engl. J. Med. 2020, 383, e63. DOI: 10.1056/NEJMp2020076.
  • van Riel, D.; de Wit, E. Next-Generation Vaccine Platforms for COVID-19. Nat. Mater. 2020, 19, 810–812. DOI: 10.1038/s41563-020-0746-0.
  • Gao, Q.; Bao, L.; Mao, H.; Wang, L.; Xu, K.; Yang, M.; Li, Y.; Zhu, L.; Wang, N.; Lv, Z.; et al. Development of an Inactivated Vaccine Candidate for SARS-CoV-2. Science 2020, 369, 77–81. DOI: 10.1126/science.abc1932.
  • Amanat, F.; Krammer, F. SARS-CoV-2 Vaccines: Status Report. Immunity 2020, 52, 583–589. DOI: 10.1016/j.immuni.2020.03.007.
  • Wrapp, D.; Wang, N.; Corbett, K. S.; Goldsmith, J. A.; Hsieh, C. L.; Abiona, O.; Graham, B. S.; McLellan, J. S. Cryo-EM Structure of the 2019-nCoV Spike in the Prefusion Conformation. Science 2020, 367, 1260–1263. DOI: 10.1126/science.abb2507.
  • Liu, C.; Zhou, Q.; Li, Y.; Garner, L. V.; Watkins, S. P.; Carter, L. J.; Smoot, J.; Gregg, A. C.; Daniels, A. D.; Jervey, S.; Albaiu, D. Research and Development on Therapeutic Agents and Vaccines for COVID-19 and Related Human Coronavirus Diseases. ACS Cent. Sci. 2020, 6, 315–331. DOI: 10.1021/acscentsci.0c00272.
  • Du, L.; He, Y.; Zhou, Y.; Liu, S.; Zheng, B. J.; Jiang, S. The Spike Protein of SARS-CoV–A Target for Vaccine and Therapeutic Development. Nat. Rev. Microbiol. 2009, 7, 226–236. DOI: 10.1038/nrmicro2090.
  • Pulendran, B.; S Arunachalam, P.; O'Hagan, D. T. Emerging Concepts in the Science of Vaccine Adjuvants. Nat. Rev. Drug Discov. 2021, 20, 454–475. DOI: 10.1038/s41573-021-00163-y.
  • Liang, Z.; Zhu, H.; Wang, X.; Jing, B.; Li, Z.; Xia, X.; Sun, H.; Yang, Y.; Zhang, W.; Shi, L.; et al. Adjuvants for Coronavirus Vaccines. Front. Immunol. 2020, 11, 589833.
  • Mousavi, T.; Sattari Saravi, S.; Valadan, R.; Haghshenas, M. R.; Rafiei, A.; Jafarpour, H.; Shamshirian, A. Different Types of Adjuvants in Prophylactic and Therapeutic Human Papillomavirus Vaccines in Laboratory Animals: A Systematic Review. Arch. Virol. 2020, 165, 263–284. DOI: 10.1007/s00705-019-04479-4.
  • Sheridan, C. First COVID-19 DNA Vaccine Approved, Others in Hot Pursuit. Nat. Biotechnol. 2021, 39, 1479–1482. DOI: 10.1038/d41587-021-00023-5.
  • Hassett, K. J.; Benenato, K. E.; Jacquinet, E.; Lee, A.; Woods, A.; Yuzhakov, O.; Himansu, S.; Deterling, J.; Geilich, B. M.; Ketova, T.; et al. Optimization of Lipid Nanoparticles for Intramuscular Administration of mRNA Vaccines. Mol. Ther. Nucleic Acids 2019, 15, 1–11. DOI: 10.1016/j.omtn.2019.01.013.
  • Malone, R. W.; Felgner, P. L.; Verma, I. M. Cationic Liposome-Mediated RNA Transfection. Proc. Natl. Acad. Sci. USA 1989, 86, 6077–6081. DOI: 10.1073/pnas.86.16.6077.
  • Martinon, F.; Krishnan, S.; Lenzen, G.; Magne, R.; Gomard, E.; Guillet, J. G.; Levy, J. P.; Meulien, P. Induction of Virus-Specific Cytotoxic T Lymphocytes in Vivo by Liposome-Entrapped mRNA. Eur. J. Immunol. 1993, 23, 1719–1722. DOI: 10.1002/eji.1830230749.
  • Weide, B.; Carralot, J. P.; Reese, A.; Scheel, B.; Eigentler, T. K.; Hoerr, I.; Rammensee, H. G.; Garbe, C.; Pascolo, S. Results of the First Phase I/II Clinical Vaccination Trial with Direct Injection of mRNA. J. Immunother. 2008, 31, 180–188. DOI: 10.1097/CJI.0b013e31815ce501.
  • Pascolo, S. Vaccines against COVID-19: Priority to mRNA-Based Formulations. Cells 2021, 10, 2716. DOI: 10.3390/cells10102716.
  • Kariko, K.; Muramatsu, H.; Welsh, F. A.; Ludwig, J.; Kato, H.; Akira, S.; Weissman, D. Incorporation of Pseudouridine into mRNA Yields Superior Nonimmunogenic Vector with Increased Translational Capacity and Biological Stability. Mol. Ther. 2008, 16, 1833–1840. DOI: 10.1038/mt.2008.200.
  • Polack, F. P.; Thomas, S. J.; Kitchin, N.; Absalon, J.; Gurtman, A.; Lockhart, S.; Perez, J. L.; Perez Marc, G.; Moreira, E. D.; Zerbini, Cet al. Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine. N. Engl. J. Med. 2020, 383, 2603–2615. Group, C. C. T DOI: 10.1056/NEJMoa2034577.
  • Cohen, J. First Self-Copying mRNA Vaccine Proves Itself in Pandemic Trial. Science 2022, 376, 446. DOI: 10.1126/science.abq7232.
  • Zepeda-Cervantes, J.; Ramirez-Jarquin, J. O.; Vaca, L. Interaction between Virus-Like Particles (VLPs) and Pattern Recognition Receptors (PRRs) from Dendritic Cells (DCs): toward Better Engineering of VLPs. Front. Immunol. 2020, 11, 1100. DOI: 10.3389/fimmu.2020.01100.
  • Shah, V. K.; Firmal, P.; Alam, A.; Ganguly, D.; Chattopadhyay, S. Overview of Immune Response during SARS-CoV-2 Infection: Lessons from the Past. Front. Immunol. 2020, 11, 1949.
  • Rosendahl Huber, S.; van Beek, J.; de Jonge, J.; Luytjes, W.; van Baarle, D. T Cell Responses to Viral Infections - Opportunities for Peptide Vaccination. Front. Immunol. 2014, 5, 171.
  • Super, M.; Doherty, E. J.; Cartwright, M. J.; Seiler, B. T.; Langellotto, F.; Dimitrakakis, N.; White, D. A.; Stafford, A. G.; Karkada, M.; Graveline, A. R.; et al. Biomaterial Vaccines Capturing Pathogen-Associated Molecular Patterns Protect against Bacterial Infections and Septic Shock. Nat. Biomed. Eng. 2022, 6, 8–18. DOI: 10.1038/s41551-021-00756-3.
  • Thames, A. H.; Wolniak, K. L.; Stupp, S. I.; Jewett, M. C. Principles Learned from the International Race to Develop a Safe and Effective COVID-19 Vaccine. ACS Cent. Sci. 2020, 6, 1341–1347. DOI: 10.1021/acscentsci.0c00644.
  • Wadhwa, A.; Aljabbari, A.; Lokras, A.; Foged, C.; Thakur, A. Opportunities and Challenges in the Delivery of mRNA-Based Vaccines. Pharmaceutics 2020, 12, 102. DOI: 10.3390/pharmaceutics12020102.
  • Ramamoorth, M.; Narvekar, A. Non Viral Vectors in Gene Therapy- An Overview. J. Clin. Diagn. Res. 2015, 9, GE01–6.
  • Zhong, Z. F.; Mc Cafferty, S.; Combes, F.; Huysmans, H.; De Temmerman, J.; Gitsels, A.; Vanrompay, D.; Catani, J. P.; Sanders, N. N. mRNA Therapeutics Deliver a Hopeful Message. Nano Today 2018, 23, 16–39. DOI: 10.1016/j.nantod.2018.10.005.
  • Maruggi, G.; Zhang, C.; Li, J.; Ulmer, J. B.; Yu, D. mRNA as a Transformative Technology for Vaccine Development to Control Infectious Diseases. Mol. Ther. 2019, 27, 757–772. DOI: 10.1016/j.ymthe.2019.01.020.
  • Nance, K. D.; Meier, J. L. Modifications in an Emergency: The Role of N1-Methylpseudouridine in COVID-19 Vaccines. ACS Cent. Sci. 2021, 7, 748–756. DOI: 10.1021/acscentsci.1c00197.
  • Reichmuth, A. M.; Oberli, M. A.; Jaklenec, A.; Langer, R.; Blankschtein, D. mRNA Vaccine Delivery Using Lipid Nanoparticles. Ther. Deliv. 2016, 7, 319–334. DOI: 10.4155/tde-2016-0006.
  • Wittrup, A.; Ai, A.; Liu, X.; Hamar, P.; Trifonova, R.; Charisse, K.; Manoharan, M.; Kirchhausen, T.; Lieberman, J. Visualizing Lipid-Formulated siRNA Release from Endosomes and Target Gene Knockdown. Nat. Biotechnol. 2015, 33, 870–876. DOI: 10.1038/nbt.3298.
  • Arteta, M. Y.; Kjellman, T.; Bartesaghi, S.; Wallin, S.; Wu, X. Q.; Kvist, A. J.; Dabkowska, A.; Szekely, N.; Radulescu, A.; Bergenholtz, J.; Lindfors, L. Successful Reprogramming of Cellular Protein Production through mRNA Delivered by Functionalized Lipid Nanoparticles. Proc. Natl. Acad. Sci. USA 2018, 115, E3351–E3360. DOI: 10.1073/pnas.1720542115.
  • Oberli, M. A.; Reichmuth, A. M.; Dorkin, J. R.; Mitchell, M. J.; Fenton, O. S.; Jaklenec, A.; Anderson, D. G.; Langer, R.; Blankschtein, D. Lipid Nanoparticle Assisted mRNA Delivery for Potent Cancer Immunotherapy. Nano Lett. 2017, 17, 1326–1335. DOI: 10.1021/acs.nanolett.6b03329.
  • Pardi, N.; Hogan, M. J.; Porter, F. W.; Weissman, D. mRNA Vaccines - A New Era in Vaccinology. Nat. Rev. Drug Discov. 2018, 17, 261–279. DOI: 10.1038/nrd.2017.243.
  • Holtkamp, S.; Kreiter, S.; Selmi, A.; Simon, P.; Koslowski, M.; Huber, C.; Tureci, O.; Sahin, U. Modification of Antigen-Encoding RNA Increases Stability, Translational Efficacy, and T-Cell Stimulatory Capacity of Dendritic Cells. Blood 2006, 108, 4009–4017. DOI: 10.1182/blood-2006-04-015024.
  • Weissman, D. mRNA Transcript Therapy. Expert Rev. Vaccines 2015, 14, 265–281. DOI: 10.1586/14760584.2015.973859.
  • Sahin, U.; Kariko, K.; Tureci, O. mRNA-Based Therapeutics–Developing a New Class of Drugs. Nat. Rev. Drug Discov. 2014, 13, 759–780. DOI: 10.1038/nrd4278.
  • Gallie, D. R. The Cap and Poly(A) Tail Function Synergistically to Regulate mRNA Translational Efficiency. Genes Dev. 1991, 5, 2108–2116. DOI: 10.1101/gad.5.11.2108.
  • Stepinski, J.; Waddell, C.; Stolarski, R.; Darzynkiewicz, E.; Rhoads, R. E. Synthesis and Properties of mRNAs Containing the Novel "anti-Reverse" Cap Analogs 7-Methyl(3'-O-Methyl)GpppG and 7-Methyl (3'-Deoxy)GpppG. RNA 2001, 7, 1486–1495.
  • Kariko, K.; Buckstein, M.; Ni, H.; Weissman, D. Suppression of RNA Recognition by Toll-like Receptors: The Impact of Nucleoside Modification and the Evolutionary Origin of RNA. Immunity 2005, 23, 165–175. DOI: 10.1016/j.immuni.2005.06.008.
  • Kormann, M. S.; Hasenpusch, G.; Aneja, M. K.; Nica, G.; Flemmer, A. W.; Herber-Jonat, S.; Huppmann, M.; Mays, L. E.; Illenyi, M.; Schams, A.; et al. Expression of Therapeutic Proteins after Delivery of Chemically Modified mRNA in Mice. Nat. Biotechnol. 2011, 29, 154–157. DOI: 10.1038/nbt.1733.
  • Wroblewska, L.; Kitada, T.; Endo, K.; Siciliano, V.; Stillo, B.; Saito, H.; Weiss, R. Mammalian Synthetic Circuits with RNA Binding Proteins for RNA-Only Delivery. Nat. Biotechnol. 2015, 33, 839–841. DOI: 10.1038/nbt.3301.
  • Warren, L.; Manos, P. D.; Ahfeldt, T.; Loh, Y. H.; Li, H.; Lau, F.; Ebina, W.; Mandal, P. K.; Smith, Z. D.; Meissner, A.; et al. Highly Efficient Reprogramming to Pluripotency and Directed Differentiation of Human Cells with Synthetic Modified mRNA. Cell Stem Cell 2010, 7, 618–630. DOI: 10.1016/j.stem.2010.08.012.
  • Anderson, B. R.; Muramatsu, H.; Nallagatla, S. R.; Bevilacqua, P. C.; Sansing, L. H.; Weissman, D.; Kariko, K. Incorporation of Pseudouridine into mRNA Enhances Translation by Diminishing PKR Activation. Nucleic Acids Res. 2010, 38, 5884–5892. DOI: 10.1093/nar/gkq347.
  • Kariko, K.; Muramatsu, H.; Ludwig, J.; Weissman, D. Generating the Optimal mRNA for Therapy: HPLC Purification Eliminates Immune Activation and Improves Translation of Nucleoside-Modified, Protein-Encoding mRNA. Nucleic Acids Res. 2011, 39, e142–e142. DOI: 10.1093/nar/gkr695.
  • Sedic, M.; Senn, J. J.; Lynn, A.; Laska, M.; Smith, M.; Platz, S. J.; Bolen, J.; Hoge, S.; Bulychev, A.; Jacquinet, E.; et al. Safety Evaluation of Lipid Nanoparticle-Formulated Modified mRNA in the Sprague-Dawley Rat and Cynomolgus Monkey. Vet. Pathol. 2018, 55, 341–354. DOI: 10.1177/0300985817738095.
  • Tanaka, H.; Nakatani, T.; Furihata, T.; Tange, K.; Nakai, Y.; Yoshioka, H.; Harashima, H.; Akita, H. In Vivo Introduction of mRNA Encapsulated in Lipid Nanoparticles to Brain Neuronal Cells and Astrocytes via Itracerebroventricular Administration. Mol. Pharm. 2018, 15, 2060–2067. DOI: 10.1021/acs.molpharmaceut.7b01084.
  • Dolgin, E. Covid Vaccine Flop Spotlights Mrna Design Challenges. Nature 2021, 594, 483–483. DOI: 10.1038/d41586-021-01661-0.
  • Pardi, N.; Tuyishime, S.; Muramatsu, H.; Kariko, K.; Mui, B. L.; Tam, Y. K.; Madden, T. D.; Hope, M. J.; Weissman, D. Expression Kinetics of Nucleoside-Modified mRNA Delivered in Lipid Nanoparticles to Mice by Various Routes. J. Control. Release 2015, 217, 345–351. DOI: 10.1016/j.jconrel.2015.08.007.
  • Xin, H.; Li, Y.; Cui, Y.; Yang, J. J.; Zhang, Z. G.; Chopp, M. Systemic Administration of Exosomes Released from Mesenchymal Stromal Cells Promote Functional Recovery and Neurovascular Plasticity after Stroke in Rats. J. Cereb. Blood Flow Metab. 2013, 33, 1711–1715. DOI: 10.1038/jcbfm.2013.152.
  • Kudla, G.; Lipinski, L.; Caffin, F.; Helwak, A.; Zylicz, M. High Guanine and Cytosine Content Increases mRNA Levels in Mammalian Cells. PLoS Biol. 2006, 4, e180. DOI: 10.1371/journal.pbio.0040180.
  • Thess, A.; Grund, S.; Mui, B. L.; Hope, M. J.; Baumhof, P.; Fotin-Mleczek, M.; Schlake, T. Sequence-Engineered mRNA without Chemical Nucleoside Modifications Enables an Effective Protein Therapy in Large Animals. Mol. Ther. 2015, 23, 1456–1464. DOI: 10.1038/mt.2015.103.
  • Henderson, J. M.; Ujita, A.; Hill, E.; Yousif-Rosales, S.; Smith, C.; Ko, N.; McReynolds, T.; Cabral, C. R.; Escamilla-Powers, J. R.; Houston, M. E. Cap 1 Messenger RNA Synthesis with Co-Transcriptional CleanCap((R)) Analog by in Vitro Transcription. Curr. Protoc. 2021, 1, e39. DOI: 10.1002/cpz1.39.
  • Benteyn, D.; Heirman, C.; Bonehill, A.; Thielemans, K.; Breckpot, K. mRNA-Based Dendritic Cell Vaccines. Expert Rev. Vaccines. 2015, 14, 161–176. DOI: 10.1586/14760584.2014.957684.
  • Boczkowski, D.; Nair, S. K.; Snyder, D.; Gilboa, E. Dendritic Cells Pulsed with RNA Are Potent Antigen-Presenting Cells in Vitro and in Vivo. J. Exp. Med. 1996, 184, 465–472. DOI: 10.1084/jem.184.2.465.
  • Kranz, L. M.; Diken, M.; Haas, H.; Kreiter, S.; Loquai, C.; Reuter, K. C.; Meng, M.; Fritz, D.; Vascotto, F.; Hefesha, H.; et al. Systemic RNA Delivery to Dendritic Cells Exploits Antiviral Defence for Cancer Immunotherapy. Nature 2016, 534, 396–401. DOI: 10.1038/nature18300.
  • Sahin, U.; Derhovanessian, E.; Miller, M.; Kloke, B. P.; Simon, P.; Lower, M.; Bukur, V.; Tadmor, A. D.; Luxemburger, U.; Schrors, B.; et al. Personalized RNA Mutanome Vaccines Mobilize Poly-Specific Therapeutic Immunity against Cancer. Nature 2017, 547, 222–226. DOI: 10.1038/nature23003.
  • Kurimoto, S.; Yoshinaga, N.; Igarashi, K.; Matsumoto, Y.; Cabral, H.; Uchida, S. PEG-OligoRNA Hybridization of mRNA for Developing Sterically Stable Lipid Nanoparticles toward in Vivo Administration. Molecules 2019, 24, 1303. DOI: 10.3390/molecules24071303.
  • Cardarelli, F.; Digiacomo, L.; Marchini, C.; Amici, A.; Salomone, F.; Fiume, G.; Rossetta, A.; Gratton, E.; Pozzi, D.; Caracciolo, G. The Intracellular Trafficking Mechanism of Lipofectamine-Based Transfection Reagents and Its Implication for Gene Delivery. Sci. Rep. 2016, 6, 25879. DOI: 10.1038/srep25879.
  • Steitz, J.; Britten, C. M.; Wolfel, T.; Tuting, T. Effective Induction of anti-Melanoma Immunity following Genetic Vaccination with Synthetic mRNA Coding for the Fusion Protein EGFP.TRP2. Cancer Immunol. Immunother. 2006, 55, 246–253. DOI: 10.1007/s00262-005-0042-5.
  • Broderick, K. E.; Humeau, L. M. Electroporation-Enhanced Delivery of Nucleic Acid Vaccines. Expert Rev. Vaccines 2015, 14, 195–204. DOI: 10.1586/14760584.2015.990890.
  • Johansson, D. X.; Ljungberg, K.; Kakoulidou, M.; Liljestrom, P. Intradermal Electroporation of Naked Replicon RNA Elicits Strong Immune Responses. PLoS One. 2012, 7, e29732. DOI: 10.1371/journal.pone.0029732.
  • Kim, J.; Eygeris, Y.; Gupta, M.; Sahay, G. Self-Assembled mRNA Vaccines. Adv. Drug Deliv. Rev. 2021, 170, 83–112. DOI: 10.1016/j.addr.2020.12.014.
  • Aldosari, B. N.; Alfagih, I. M.; Almurshedi, A. S. Lipid Nanoparticles as Delivery Systems for RNA-Based Vaccines. Pharmaceutics 2021, 13, 206. DOI: 10.3390/pharmaceutics13020206.
  • Williams, D. J.; Puhl, H. L.; Ikeda, S. R. A Simple, Highly Efficient Method for Heterologous Expression in Mammalian Primary Neurons Using Cationic Lipid-Mediated mRNA Transfection. Front. Neurosci. 2010, 4, 181. DOI: 10.3389/fnins.2010.00181.
  • Fang, N.; Wang, J.; Mao, H. Q.; Leong, K. W.; Chan, V. BHEM-Chol/DOPE Liposome Induced Perturbation of Phospholipid Bilayer. Colloids Surfaces B Biointerfaces 2003, 29, 233–245. DOI: 10.1016/S0927-7765(02)00207-2.
  • Zhang, Y.; Shen, S.; Zhao, G.; Xu, C. F.; Zhang, H. B.; Luo, Y. L.; Cao, Z. T.; Shi, J.; Zhao, Z. B.; Lian, Z. X.; Wang, J. In Situ Repurposing of Dendritic Cells with CRISPR/Cas9-Based Nanomedicine to Induce Transplant Tolerance. Biomaterials 2019, 217, 119302. DOI: 10.1016/j.biomaterials.2019.119302.
  • Kauffman, K. J.; Webber, M. J.; Anderson, D. G. Materials for Non-Viral Intracellular Delivery of Messenger RNA Therapeutics. J. Control. Release 2016, 240, 227–234. DOI: 10.1016/j.jconrel.2015.12.032.
  • Guan, S.; Rosenecker, J. Nanotechnologies in Delivery of mRNA Therapeutics Using Nonviral Vector-Based Delivery Systems. Gene Ther. 2017, 24, 133–143. DOI: 10.1038/gt.2017.5.
  • Midoux, P.; Pichon, C. Lipid-Based mRNA Vaccine Delivery Systems. Expert Rev. Vaccines 2015, 14, 221–234. DOI: 10.1586/14760584.2015.986104.
  • Kaczmarek, J. C.; Patel, A. K.; Kauffman, K. J.; Fenton, O. S.; Webber, M. J.; Heartlein, M. W.; DeRosa, F.; Anderson, D. G. Polymer-Lipid Nanoparticles for Systemic Delivery of mRNA to the Lungs. Angew. Chem. Int. Ed. Engl. 2016, 55, 13808–13812. DOI: 10.1002/anie.201608450.
  • Eltoukhy, A. A.; Chen, D.; Alabi, C. A.; Langer, R.; Anderson, D. G. Degradable Terpolymers with Alkyl Side Chains Demonstrate Enhanced Gene Delivery Potency and Nanoparticle Stability. Adv. Mater. 2013, 25, 1487–1493. DOI: 10.1002/adma.201204346.
  • Su, X. F.; Fricke, J.; Kavanagh, D. G.; Irvine, D. J. In Vitro and in Vivo mRNA Delivery Using Lipid-Enveloped pH-Responsive Polymer Nanoparticles. Mol. Pharm. 2011, 8, 774–787. DOI: 10.1021/mp100390w.
  • Guerrero-Cazares, H.; Tzeng, S. Y.; Young, N. P.; Abutaleb, A. O.; Quinones-Hinojosa, A.; Green, J. J. Biodegradable Polymeric Nanoparticles Show High Efficacy and Specificity at DNA Delivery to Human Glioblastoma in Vitro and in Vivo. ACS Nano. 2014, 8, 5141–5153. DOI: 10.1021/nn501197v.
  • Mastorakos, P.; da Silva, A. L.; Chisholm, J.; Song, E.; Choi, W. K.; Boyle, M. P.; Morales, M. M.; Hanes, J.; Suk, J. S. Highly Compacted Biodegradable DNA Nanoparticles Capable of Overcoming the Mucus Barrier for Inhaled Lung Gene Therapy. Proc. Natl. Acad. Sci. USA 2015, 112, 8720–8725. DOI: 10.1073/pnas.1502281112.
  • Ross-Thriepland, D.; Bornot, A.; Butler, L.; Desai, A.; Jaiswal, H.; Peel, S.; Hunter, M. R.; Odunze, U.; Isherwood, B.; Gianni, D. Arrayed CRISPR Screening Identifies Novel Targets That Enhance the Productive Delivery of mRNA by MC3-Based Lipid Nanoparticles. SLAS Discov. 2020, 25, 605–617. DOI: 10.1177/2472555220925770.
  • Xue, H. Y.; Guo, P.; Wen, W. C.; Wong, H. L. Lipid-Based Nanocarriers for RNA Delivery. Curr. Pharm. Des. 2015, 21, 3140–3147. DOI: 10.2174/1381612821666150531164540.
  • Viger-Gravel, J.; Schantz, A.; Pinon, A. C.; Rossini, A. J.; Schantz, S.; Emsley, L. Structure of Lipid Nanoparticles Containing siRNA or mRNA by Dynamic Nuclear Polarization-Enhanced NMR Spectroscopy. J. Phys. Chem. B 2018, 122, 2073–2081. DOI: 10.1021/acs.jpcb.7b10795.
  • Corbett, K. S.; Edwards, D.; Leist, S. R.; Abiona, O. M.; Boyoglu-Barnum, S.; Gillespie, R. A.; Himansu, S.; Schafer, A.; Ziwawo, C. T.; DiPiazza, A. T.; et al. SARS-CoV-2 mRNA Vaccine Development Enabled by Prototype Pathogen Preparedness. bioRxiv 2020. Doi: 10.1101/2020.06.11.145920.
  • Guevara, M. L.; Persano, S.; Persano, F. Lipid-Based Vectors for Therapeutic mRNA-Based anti-Cancer Vaccines. Curr. Pharm. Des. 2019, 25, 1443–1454. DOI: 10.2174/1381612825666190619150221.
  • Nabhan, J. F.; Wood, K. M.; Rao, V. P.; Morin, J.; Bhamidipaty, S.; LaBranche, T. P.; Gooch, R. L.; Bozal, F.; Bulawa, C. E.; Guild, B. C. Intrathecal Delivery of Frataxin mRNA Encapsulated in Lipid Nanoparticles to Dorsal Root Ganglia as a Potential Therapeutic for Friedreich's Ataxia. Sci. Rep. 2016, 6, 20019. DOI: 10.1038/srep20019.
  • Kon, E.; Hazan-Halevy, I.; Rosenblum, D.; Cohen, N.; Chatterjee, S.; Veiga, N.; Raanani, P.; Bairey, O.; Benjamini, O.; Nagler, A.; Peer, D. Resveratrol Enhances mRNA and siRNA Lipid Nanoparticles Primary CLL Cell Transfection. Pharmaceutics 2020, 12, 520. DOI: 10.3390/pharmaceutics12060520.
  • Mukherjee, A.; MacDonald, K. D.; Kim, J.; Henderson, M. I.; Eygeris, Y.; Sahay, G. Engineered Mutant alpha-ENaC Subunit mRNA Delivered by Lipid Nanoparticles Reduces Amiloride Currents in Cystic Fibrosis-Based Cell and Mice Models. Sci. Adv. 2020, 6, eabc5911.
  • Zhang, H. R.; Leal, J.; Soto, M. R.; Smyth, H. D. C.; Ghosh, D. Aerosolizable Lipid Nanoparticles for Pulmonary Delivery of mRNA through Design of Experiments. Pharmaceutics 2020, 12, 1042. DOI: 10.3390/pharmaceutics12111042.
  • Riley, R. S.; Kashyap, M. V.; Billingsley, M. M.; White, B.; Alameh, M. G.; Bose, S. K.; Zoltick, P. W.; Li, H.; Zhang, R.; Cheng, A. Y.; et al. Ionizable Lipid Nanoparticles for in Utero mRNA Delivery. Sci Adv 2021, 7, eaba1028.
  • Billingsley, M. M.; Singh, N.; Ravikumar, P.; Zhang, R.; June, C. H.; Mitchell, M. J. Ionizable Lipid Nanoparticle-Mediated mRNA Delivery for Human CAR T Cell Engineering. Nano Lett. 2020, 20, 1578–1589. DOI: 10.1021/acs.nanolett.9b04246.
  • Richner, J. M.; Himansu, S.; Dowd, K. A.; Butler, S. L.; Salazar, V.; Fox, J. M.; Julander, J. G.; Tang, W. W.; Shresta, S.; Pierson, T. C.; et al. Modified mRNA Vaccines Protect against Zika Virus Infection. Cell 2017, 168, 1114–1125 e10. DOI: 10.1016/j.cell.2017.02.017.
  • Buschmann, M. D.; Carrasco, M. J.; Alishetty, S.; Paige, M.; Alameh, M. G.; Weissman, D. Nanomaterial Delivery Systems for mRNA Vaccines. Vaccines (Basel) 2021, 9, 65. DOI: 10.3390/vaccines9010065.
  • Dong, Y.; Love, K. T.; Dorkin, J. R.; Sirirungruang, S.; Zhang, Y.; Chen, D.; Bogorad, R. L.; Yin, H.; Chen, Y.; Vegas, A. J.; et al. Lipopeptide Nanoparticles for Potent and Selective siRNA Delivery in Rodents and Nonhuman Primates. Proc. Natl. Acad. Sci. USA 2014, 111, 3955–3960. DOI: 10.1073/pnas.1322937111.
  • Cheng, Q.; Wei, T.; Jia, Y.; Farbiak, L.; Zhou, K.; Zhang, S.; Wei, Y.; Zhu, H.; Siegwart, D. J. Dendrimer-Based Lipid Nanoparticles Deliver Therapeutic FAH mRNA to Normalize Liver Function and Extend Survival in a Mouse Model of Hepatorenal Tyrosinemia Type I. Adv. Mater. 2018, 30, e1805308. DOI: 10.1002/adma.201805308.
  • Markov, O. V.; Mironova, N. L.; Shmendel, E. V.; Serikov, R. N.; Morozova, N. G.; Maslov, M. A.; Vlassov, V. V.; Zenkova, M. A. Multicomponent Mannose-Containing Liposomes Efficiently Deliver RNA in Murine Immature Dendritic Cells and Provide Productive anti-Tumour Response in Murine Melanoma Model. J. Control. Release 2015, 213, 45–56. DOI: 10.1016/j.jconrel.2015.06.028.
  • Love, K. T.; Mahon, K. P.; Levins, C. G.; Whitehead, K. A.; Querbes, W.; Dorkin, J. R.; Qin, J.; Cantley, W.; Qin, L. L.; Racie, T.; et al. Lipid-like Materials for Low-Dose, in Vivo Gene Silencing. Proc. Natl. Acad. Sci. USA 2010, 107, 1864–1869. DOI: 10.1073/pnas.0910603106.
  • Zhang, X.; Zhao, W.; Nguyen, G. N.; Zhang, C.; Zeng, C.; Yan, J.; Du, S.; Hou, X.; Li, W.; Jiang, J.; et al. Functionalized Lipid-like Nanoparticles for in Vivo mRNA Delivery and Base Editing. Sci. Adv. 2020, 6, eabc2315.
  • Kaczmarek, J. C.; Kauffman, K. J.; Fenton, O. S.; Sadtler, K.; Patel, A. K.; Heartlein, M. W.; DeRosa, F.; Anderson, D. G. Optimization of a Degradable Polymer-Lipid Nanoparticle for Potent Systemic Delivery of mRNA to the Lung Endothelium and Immune Cells. Nano Lett. 2018, 18, 6449–6454. DOI: 10.1021/acs.nanolett.8b02917.
  • Patel, S.; Ashwanikumar, N.; Robinson, E.; Xia, Y.; Mihai, C.; Griffith, J. P.; Hou, S.; Esposito, A. A.; Ketova, T.; Welsher, K.; et al. Naturally-Occurring Cholesterol Analogues in Lipid Nanoparticles Induce Polymorphic Shape and Enhance Intracellular Delivery of mRNA. Nat. Commun. 2020, 11, 983. DOI: 10.1038/s41467-020-14527-2.
  • Robinson, E.; MacDonald, K. D.; Slaughter, K.; McKinney, M.; Patel, S.; Sun, C.; Sahay, G. Lipid Nanoparticle-Delivered Chemically Modified mRNA Restores Chloride Secretion in Cystic Fibrosis. Mol. Ther. 2018, 26, 2034–2046. DOI: 10.1016/j.ymthe.2018.05.014.
  • Novakowski, S.; Jiang, K.; Prakash, G.; Kastrup, C. Delivery of mRNA to Platelets Using Lipid Nanoparticles. Sci. Rep. 2019, 9. DOI: 10.1038/s41598-018-36910-2.
  • Luo, X.; Li, B.; Zhang, X.; Zhao, W.; Bratasz, A.; Deng, B.; McComb, D. W.; Dong, Y. Dual-Functional Lipid-like Nanoparticles for Delivery of mRNA and MRI Contrast Agents. Nanoscale 2017, 9, 1575–1579. DOI: 10.1039/c6nr08496f.
  • Patel, S.; Ashwanikumar, N.; Robinson, E.; DuRoss, A.; Sun, C.; Murphy-Benenato, K. E.; Mihai, C.; Almarsson, O.; Sahay, G. Boosting Intracellular Delivery of Lipid Nanoparticle-Encapsulated mRNA. Nano Lett. 2017, 17, 5711–5718. DOI: 10.1021/acs.nanolett.7b02664.
  • Li, B.; Luo, X.; Deng, B.; Wang, J.; McComb, D. W.; Shi, Y.; Gaensler, K. M.; Tan, X.; Dunn, A. L.; Kerlin, B. A.; Dong, Y. An Orthogonal Array Optimization of Lipid-like Nanoparticles for mRNA Delivery in Vivo. Nano Lett. 2015, 15, 8099–8107. DOI: 10.1021/acs.nanolett.5b03528.
  • Kanasty, R.; Dorkin, J. R.; Vegas, A.; Anderson, D. Delivery Materials for siRNA Therapeutics. Nat. Mater. 2013, 12, 967–977. DOI: 10.1038/nmat3765.
  • Bahl, K.; Senn, J. J.; Yuzhakov, O.; Bulychev, A.; Brito, L. A.; Hassett, K. J.; Laska, M. E.; Smith, M.; Almarsson, O.; Thompson, J.; et al. Preclinical and Clinical Demonstration of Immunogenicity by mRNA Vaccines against H10N8 and H7N9 Influenza Viruses. Mol. Ther. 2017, 25, 1316–1327. DOI: 10.1016/j.ymthe.2017.03.035.
  • Tam, H. H.; Melo, M. B.; Kang, M.; Pelet, J. M.; Ruda, V. M.; Foley, M. H.; Hu, J. K.; Kumari, S.; Crampton, J.; Baldeon, A. D.; et al. Sustained Antigen Availability during Germinal Center Initiation Enhances Antibody Responses to Vaccination. Proc. Natl. Acad. Sci. USA 2016, 113, E6639–E6648.
  • Pardi, N.; Hogan, M. J.; Pelc, R. S.; Muramatsu, H.; Andersen, H.; DeMaso, C. R.; Dowd, K. A.; Sutherland, L. L.; Scearce, R. M.; Parks, R.; et al. Zika Virus Protection by a Single Low-Dose Nucleoside-Modified mRNA Vaccination. Nature 2017, 543, 248–251. DOI: 10.1038/nature21428.
  • Havenar-Daughton, C.; Lee, J. H.; Crotty, S. Tfh Cells and HIV bnAbs, an Immunodominance Model of the HIV Neutralizing Antibody Generation Problem. Immunol. Rev. 2017, 275, 49–61. DOI: 10.1111/imr.12512.
  • Kauffman, K. J.; Dorkin, J. R.; Yang, J. H.; Heartlein, M. W.; DeRosa, F.; Mir, F. F.; Fenton, O. S.; Anderson, D. G. Optimization of Lipid Nanoparticle Formulations for mRNA Delivery in Vivo with Fractional Factorial and Definitive Screening Designs. Nano Lett. 2015, 15, 7300–7306. DOI: 10.1021/acs.nanolett.5b02497.
  • Guevara, M. L.; Persano, F.; Persano, S. Advances in Lipid Nanoparticles for mRNA-Based Cancer Immunotherapy. Front. Chem. 2020, 8, 589959.
  • Fan, Y. N.; Li, M.; Luo, Y. L.; Chen, Q.; Wang, L.; Zhang, H. B.; Shen, S.; Gu, Z.; Wang, J. Cationic Lipid-Assisted Nanoparticles for Delivery of mRNA Cancer Vaccine. Biomater. Sci. 2018, 6, 3009–3018. DOI: 10.1039/c8bm00908b.
  • Li, Q.; Chan, C.; Peterson, N.; Hanna, R. N.; Alfaro, A.; Allen, K. L.; Wu, H.; Dall'Acqua, W. F.; Borrok, M. J.; Santos, J. L. Engineering Caveolae-Targeted Lipid Nanoparticles to Deliver mRNA to the Lungs. ACS Chem. Biol. 2020, 15, 830–836. DOI: 10.1021/acschembio.0c00003.
  • Espeseth, A. S.; Cejas, P. J.; Citron, M. P.; Wang, D.; DiStefano, D. J.; Callahan, C.; Donnell, G. O.; Galli, J. D.; Swoyer, R.; Touch, S.; et al. Modified mRNA/Lipid Nanoparticle-Based Vaccines Expressing Respiratory Syncytial Virus F Protein Variants Are Immunogenic and Protective in Rodent Models of RSV Infection. NPJ Vaccines. 2020, 5, 16. DOI: 10.1038/s41541-020-0163-z.
  • Cullis, P. R.; Hope, M. J. Lipid Nanoparticle Systems for Enabling Gene Therapies. Mol. Ther. 2017, 25, 1467–1475. DOI: 10.1016/j.ymthe.2017.03.013.
  • Kauffman, K. J.; Mir, F. F.; Jhunjhunwala, S.; Kaczmarek, J. C.; Hurtado, J. E.; Yang, J. H.; Webber, M. J.; Kowalski, P. S.; Heartlein, M. W.; DeRosa, F.; Anderson, D. G. Efficacy and Immunogenicity of Unmodified and Pseudouridine-Modified mRNA Delivered Systemically with Lipid Nanoparticles in Vivo. Biomaterials 2016, 109, 78–87. DOI: 10.1016/j.biomaterials.2016.09.006.
  • Ball, R. L.; Hajj, K. A.; Vizelman, J.; Bajaj, P.; Whitehead, K. A. Lipid Nanoparticle Formulations for Enhanced Co-Delivery of siRNA and mRNA. Nano Lett. 2018, 18, 3814–3822. DOI: 10.1021/acs.nanolett.8b01101.
  • Hajj, K. A.; Ball, R. L.; Deluty, S. B.; Singh, S. R.; Strelkova, D.; Knapp, C. M.; Whitehead, K. A. Branched-Tail Lipid Nanoparticles Potently Deliver mRNA in Vivo Due to Enhanced Ionization at Endosomal pH. Small 2019, 15, e1805097.
  • Zhao, P.; Hou, X.; Yan, J.; Du, S.; Xue, Y.; Li, W.; Xiang, G.; Dong, Y. Long-Term Storage of Lipid-like Nanoparticles for mRNA Delivery. Bioact. Mater. 2020, 5, 358–363. DOI: 10.1016/j.bioactmat.2020.03.001.
  • Miwa, T.; Saito, H.; Akita, H. Lipid Nanoparticles-Encapsulated Brain-Derived Neurotrophic Factor mRNA Delivered through the Round Window Niche in the Cochleae of guinea Pigs. Exp. Brain Res. 2021, 239, 425–433. DOI: 10.1007/s00221-020-05970-0.
  • Nogueira, S. S.; Schlegel, A.; Maxeiner, K.; Weber, B.; Barz, M.; Schroer, M. A.; Blanchet, C. E.; Svergun, D. I.; Ramishetti, S.; Peer, D.; et al. Polysarcosine-Functionalized Lipid Nanoparticles for Therapeutic mRNA Delivery. ACS Appl. Nano Mater. 2020, 3, 10634–10645. DOI: 10.1021/acsanm.0c01834.
  • Pichon, C.; Midoux, P. Mannosylated and Histidylated LPR Technology for Vaccination with Tumor Antigen mRNA. Methods Mol. Biol. 2013, 969, 247–274.
  • Zhuang, X.; Qi, Y.; Wang, M.; Yu, N.; Nan, F.; Zhang, H.; Tian, M.; Li, C.; Lu, H.; Jin, N. mRNA Vaccines Encoding the HA Protein of Influenza a H1N1 Virus Delivered by Cationic Lipid Nanoparticles Induce Protective Immune Responses in Mice. Vaccines (Basel) 2020, 8, 123. DOI: 10.3390/vaccines8010123.
  • Pappalardo, J. S.; Salmaso, S.; Levchenko, T. S.; Mastrotto, F.; Bersani, S.; Langellotti, C. A.; Vermeulen, M.; Ghersa, F.; Quattrocchi, V.; Zamorano, P. I.; et al. Characterization of a Nanovaccine Platform Based on an Alpha 1,2-Mannobiose Derivative Shows Species-Non-Specific Targeting to Human, Bovine, Mouse, and Teleost Fish Dendritic Cells. Mol. Pharm. 2021, 18, 2540–2555. DOI: 10.1021/acs.molpharmaceut.1c00048.
  • Kumar, V.; Qin, J.; Jiang, Y.; Duncan, R. G.; Brigham, B.; Fishman, S.; Nair, J. K.; Akinc, A.; Barros, S. A.; Kasperkovitz, P. V. Shielding of Lipid Nanoparticles for siRNA Delivery: Impact on Physicochemical Properties, Cytokine Induction, and Efficacy. Mol. Ther. Nucleic Acids. 2014, 3, e210. DOI: 10.1038/mtna.2014.61.
  • Knop, K.; Hoogenboom, R.; Fischer, D.; Schubert, U. S. Poly(Ethylene Glycol) in Drug Delivery: Pros and Cons as Well as Potential Alternatives. Angew. Chem. Int. Ed. Engl. 2010, 49, 6288–6308. DOI: 10.1002/anie.200902672.
  • Gangloff, N.; Ulbricht, J.; Lorson, T.; Schlaad, H.; Luxenhofer, R. Peptoids and Polypeptoids at the Frontier of Supra- and Macromolecular Engineering. Chem. Rev. 2016, 116, 1753–1802. DOI: 10.1021/acs.chemrev.5b00201.
  • Secker, C.; Brosnan, S. M.; Luxenhofer, R.; Schlaad, H. Poly(alpha-Peptoid)s Revisited: Synthesis, Properties, and Use as Biomaterial. Macromol. Biosci. 2015, 15, 881–891. DOI: 10.1002/mabi.201500023.
  • Fenaroli, F.; Repnik, U.; Xu, Y. T.; Johann, K.; Van Herck, S.; Dey, P.; Skjeldal, F. M.; Frei, D. M.; Bagherifam, S.; Kocere, A.; et al. Enhanced Permeability and Retention-like Extravasation of Nanoparticles from the Vasculature into Tuberculosis Granulomas in Zebrafish and Mouse Models. ACS Nano. 2018, 12, 8646–8661. DOI: 10.1021/acsnano.8b04433.
  • Weber, B.; Seidl, C.; Schwiertz, D.; Scherer, M.; Bleher, S.; Suss, R.; Barz, M. Polysarcosine-Based Lipids: From Lipopolypeptoid Micelles to Stealth-Like Lipids in Langmuir Blodgett Monolayers. Polymers (Basel) 2016, 8, 427. DOI: 10.3390/polym8120427.
  • Whitehead, K. A.; Dorkin, J. R.; Vegas, A. J.; Chang, P. H.; Veiseh, O.; Matthews, J.; Fenton, O. S.; Zhang, Y.; Olejnik, K. T.; Yesilyurt, V.; et al. Degradable Lipid Nanoparticles with Predictable in Vivo siRNA Delivery Activity. Nat. Commun. 2014, 5, 4277. DOI: 10.1038/ncomms5277.
  • Guimaraes, P. P. G.; Zhang, R.; Spektor, R.; Tan, M.; Chung, A.; Billingsley, M. M.; El-Mayta, R.; Riley, R. S.; Wang, L.; Wilson, J. M.; Mitchell, M. J. Ionizable Lipid Nanoparticles Encapsulating Barcoded mRNA for Accelerated in Vivo Delivery Screening. J. Control. Release 2019, 316, 404–417. DOI: 10.1016/j.jconrel.2019.10.028.
  • Lou, G.; Anderluzzi, G.; Schmidt, S. T.; Woods, S.; Gallorini, S.; Brazzoli, M.; Giusti, F.; Ferlenghi, I.; Johnson, R. N.; Roberts, C. W.; et al. Delivery of Self-Amplifying mRNA Vaccines by Cationic Lipid Nanoparticles: The Impact of Cationic Lipid Selection. J. Control. Release 2020, 325, 370–379. DOI: 10.1016/j.jconrel.2020.06.027.
  • Lee, E. R.; Marshall, J.; Siegel, C. S.; Jiang, C.; Yew, N. S.; Nichols, M. R.; Nietupski, J. B.; Ziegler, R. J.; Lane, M. B.; Wang, K. X.; et al. Detailed Analysis of Structures and Formulations of Cationic Lipids for Efficient Gene Transfer to the Lung. Hum. Gene Ther. 1996, 7, 1701–1717. DOI: 10.1089/hum.1996.7.14-1701.
  • Gao, X.; Huang, L. A Novel Cationic Liposome Reagent for Efficient Transfection of Mammalian Cells. Biochem. Biophys. Res. Commun. 1991, 179, 280–285. DOI: 10.1016/0006-291X(91)91366-K.
  • Ewert, K.; Ahmad, A.; Evans, H. M.; Schmidt, H. W.; Safinya, C. R. Efficient Synthesis and Cell-Transfection Properties of a New Multivalent Cationic Lipid for Nonviral Gene Delivery. J. Med. Chem. 2002, 45, 5023–5029. DOI: 10.1021/jm020233w.
  • Kichler, A.; Mechtler, K.; Behr, J. P.; Wagner, E. Influence of Membrane-Active Peptides on Lipospermine/DNA Complex Mediated Gene Transfer. Bioconjug. Chem. 1997, 8, 213–221. DOI: 10.1021/bc970009z.
  • Jayaraman, M.; Ansell, S. M.; Mui, B. L.; Tam, Y. K.; Chen, J.; Du, X.; Butler, D.; Eltepu, L.; Matsuda, S.; Narayanannair, J. K.; et al. Maximizing the Potency of siRNA Lipid Nanoparticles for Hepatic Gene Silencing in Vivo. Angew. Chem. Int. Ed. Engl. 2012, 51, 8529–8533. DOI: 10.1002/anie.201203263.
  • Kulkarni, J. A.; Cullis, P. R.; van der Meel, R. Lipid Nanoparticles Enabling Gene Therapies: From Concepts to Clinical Utility. Nucleic Acid Ther. 2018, 28, 146–157. DOI: 10.1089/nat.2018.0721.
  • Schlich, M.; Palomba, R.; Costabile, G.; Mizrahy, S.; Pannuzzo, M.; Peer, D.; Decuzzi, P. Cytosolic Delivery of Nucleic Acids: The Case of Ionizable Lipid Nanoparticles. Bioeng. Transl. Med. 2021, 6, e10213. DOI: 10.1002/btm2.10213.
  • Maugeri, M.; Nawaz, M.; Papadimitriou, A.; Angerfors, A.; Camponeschi, A.; Na, M.; Holtta, M.; Skantze, P.; Johansson, S.; Sundqvist, M.; et al. Linkage between Endosomal Escape of LNP-mRNA and Loading into EVs for Transport to Other Cells. Nat. Commun. 2019, 10, 4333. DOI: 10.1038/s41467-019-12275-6.
  • Ramishetti, S.; Hazan-Halevy, I.; Palakuri, R.; Chatterjee, S.; Naidu Gonna, S.; Dammes, N.; Freilich, I.; Kolik Shmuel, L.; Danino, D.; Peer, D. A Combinatorial Library of Lipid Nanoparticles for RNA Delivery to Leukocytes. Adv. Mater. 2020, 32, e1906128. DOI: 10.1002/adma.201906128.
  • Maier, M. A.; Jayaraman, M.; Matsuda, S.; Liu, J.; Barros, S.; Querbes, W.; Tam, Y. K.; Ansell, S. M.; Kumar, V.; Qin, J.; et al. Biodegradable Lipids Enabling Rapidly Eliminated Lipid Nanoparticles for Systemic Delivery of RNAi Therapeutics. Mol. Ther. 2013, 21, 1570–1578. DOI: 10.1038/mt.2013.124.
  • Hobo, W.; Novobrantseva, T. I.; Fredrix, H.; Wong, J.; Milstein, S.; Epstein-Barash, H.; Liu, J.; Schaap, N.; van der Voort, R.; Dolstra, H. Improving Dendritic Cell Vaccine Immunogenicity by Silencing PD-1 Ligands Using siRNA-Lipid Nanoparticles Combined with Antigen mRNA Electroporation. Cancer Immunol. Immunother. 2013, 62, 285–297. DOI: 10.1007/s00262-012-1334-1.
  • Hajj, K. A.; Melamed, J. R.; Chaudhary, N.; Lamson, N. G.; Ball, R. L.; Yerneni, S. S.; Whitehead, K. A. A Potent Branched-Tail Lipid Nanoparticle Enables Multiplexed mRNA Delivery and Gene Editing in Vivo. Nano Lett. 2020, 20, 5167–5175. DOI: 10.1021/acs.nanolett.0c00596.
  • Xiong, H.; Liu, S.; Wei, T.; Cheng, Q.; Siegwart, D. J. Theranostic Dendrimer-Based Lipid Nanoparticles Containing PEGylated BODIPY Dyes for Tumor Imaging and Systemic mRNA Delivery In Vivo. J. Control. Release 2020, 325, 198–205. DOI: 10.1016/j.jconrel.2020.06.030.
  • Matsui, H.; Sato, Y.; Hatakeyama, H.; Akita, H.; Harashima, H. Size-Dependent Specific Targeting and Efficient Gene Silencing in Peritoneal Macrophages Using a pH-Sensitive Cationic Liposomal siRNA Carrier. Int. J. Pharm. 2015, 495, 171–178. DOI: 10.1016/j.ijpharm.2015.08.044.
  • Islam, M. A.; Xu, Y.; Tao, W.; Ubellacker, J. M.; Lim, M.; Aum, D.; Lee, G. Y.; Zhou, K.; Zope, H.; Yu, M.; et al. Restoration of Tumour-Growth Suppression In Vivo via Systemic Nanoparticle-Mediated Delivery of PTEN mRNA. Nat. Biomed. Eng. 2018, 2, 850–864. DOI: 10.1038/s41551-018-0284-0.
  • Hou, X.; Zaks, T.; Langer, R.; Dong, Y. Lipid Nanoparticles for mRNA Delivery. Nat. Rev. Mater. 2021, 6, 1078–1094. DOI: 10.1038/s41578-021-00400-1.
  • Blakney, A. K.; McKay, P. F.; Bouton, C. R.; Hu, K.; Samnuan, K.; Shattock, R. J. Innate Inhibiting Proteins Enhance Expression and Immunogenicity of Self-Amplifying RNA. Mol. Ther. 2021, 29, 1174–1185. DOI: 10.1016/j.ymthe.2020.11.011.
  • Blakney, A. K.; Zhu, Y. Q.; McKay, P. F.; Bouton, C. R.; Yeow, J.; Tang, J. Q.; Hu, K.; Samnuan, K.; Grigsby, C. L.; Shattock, R. J.; Stevens, M. M. Big is Beautiful: Enhanced saRNA Delivery and Immunogenicity by a Higher Molecular Weight, Bioreducible, Cationic Polymer. ACS Nano 2020, 14, 5711–5727. DOI: 10.1021/acsnano.0c00326.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.